HK1061201A1 - Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor - Google Patents

Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor

Info

Publication number
HK1061201A1
HK1061201A1 HK04104296.9A HK04104296A HK1061201A1 HK 1061201 A1 HK1061201 A1 HK 1061201A1 HK 04104296 A HK04104296 A HK 04104296A HK 1061201 A1 HK1061201 A1 HK 1061201A1
Authority
HK
Hong Kong
Prior art keywords
antigen
hepatitis
inhibitor
compound interferon
super compound
Prior art date
Application number
HK04104296.9A
Other languages
English (en)
Inventor
Guangwen Wei
Rongbing Guo
Renhuai Zhang
Original Assignee
Sichuan Biotechnology Res Ct B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Biotechnology Res Ct B filed Critical Sichuan Biotechnology Res Ct B
Publication of HK1061201A1 publication Critical patent/HK1061201A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
HK04104296.9A 2001-02-28 2004-06-15 Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor HK1061201A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB011043679A CN1245215C (zh) 2001-02-28 2001-02-28 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
PCT/CN2002/000128 WO2002080958A1 (fr) 2001-02-28 2002-02-28 Interferon supercompose de recombinaison utilise comme inhibiteur de l'antigene de surface et de l'antigene e de l'hepatite b

Publications (1)

Publication Number Publication Date
HK1061201A1 true HK1061201A1 (en) 2004-09-10

Family

ID=4653854

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04104296.9A HK1061201A1 (en) 2001-02-28 2004-06-15 Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor

Country Status (10)

Country Link
US (3) US7364724B2 (xx)
EP (1) EP1371373B1 (xx)
JP (1) JP4617058B2 (xx)
CN (1) CN1245215C (xx)
AT (1) ATE446104T1 (xx)
AU (1) AU2003248419B2 (xx)
CA (1) CA2439503A1 (xx)
DE (1) DE60234085D1 (xx)
HK (1) HK1061201A1 (xx)
WO (1) WO2002080958A1 (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060035327A1 (en) * 2001-02-28 2006-02-16 Guangwen Wei Recombinant super-compound interferon and uses thereof
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US20050079579A1 (en) * 2001-02-28 2005-04-14 Guangwen Wei Uses of spatial configuration to modulate protein function
US7335496B2 (en) * 2003-06-05 2008-02-26 Ajinomoto Co., Inc. Method for producing target substance
AU2011202683B2 (en) * 2003-08-28 2012-08-09 Superlab Far East Limited Uses of interferons with altered spatial structure
JP2007503812A (ja) * 2003-08-28 2007-03-01 ヒュイヤンテック（ユーエスエー），インク． 空間構造によるタンパク質の機能の調節
SI2325202T1 (sl) * 2003-08-28 2015-02-27 Superlab Far East Limited Uporabe interferonov s spremenjeno prostorsko strukturo
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
CN1740197B (zh) * 2004-08-26 2010-05-12 辉阳科技美国公司 具有全新空间构象且功效增强的重组干扰素、其制备方法及应用
US20080124302A1 (en) * 2005-03-09 2008-05-29 Guangwen Wei Uses of Recombinant Super-Compound Interferons
CN101525381B (zh) * 2008-03-04 2012-04-18 北京百川飞虹生物科技有限公司 一种重组复合干扰素及其表达载体的构建和表达
CN102101886A (zh) * 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
WO2013055811A1 (en) * 2011-10-12 2013-04-18 Hitachi Chemical Co., Ltd. Ex vivo methods of predicting responsiveness of a subject to interferon therapy
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
TW201427681A (zh) 2013-01-07 2014-07-16 Superlab Far East Ltd 用空間構象改變的重組干擾素治療腫瘤的方法
ES2768702T3 (es) 2013-11-13 2020-06-23 Superlab Far East Ltd Procedimientos para determinar interferón que tiene efectos inhibidores directos sobre tumores y usos del mismo
WO2016180335A1 (en) 2015-05-12 2016-11-17 Superlab Far East Limited Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0083734B1 (de) 1981-12-07 1986-03-05 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Kristallines Human-Leukocyten-Interferon
US4672108A (en) * 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4462940A (en) 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4681930A (en) * 1983-09-20 1987-07-21 Hoffmann-La Roche Inc. Immune interferon and a method for its extraction and purification
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
DE4329756A1 (de) 1993-09-03 1995-03-09 Boehringer Ingelheim Int Verfahren zur Herstellung und Reinigung von alpha-Interferon
EP0626448A3 (de) 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
EP0861321B1 (en) 1995-10-13 2006-05-31 President And Fellows Of Harvard College Phosphopantetheinyl transferases and uses thereof
US5972331A (en) * 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
US5874304A (en) * 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US6532437B1 (en) * 1996-10-23 2003-03-11 Cornell Research Foundation, Inc. Crystalline frap complex
CN1186120A (zh) 1996-12-24 1998-07-01 深圳科兴生物制品有限公司 在大肠杆菌中表达作为分泌的重组人干扰素α1b蛋白
AU1619699A (en) * 1997-12-05 1999-06-28 Human Genome Sciences, Inc. Synferon, a synthetic type i interferon
US6087478A (en) * 1998-01-23 2000-07-11 The Rockefeller University Crystal of the N-terminal domain of a STAT protein and methods of use thereof
BR9907964A (pt) 1998-02-06 2000-10-17 Ilexus Pty Limited Estruturas tridimensionais e modelos de receptores fc e usos dos mesmos
CN1062565C (zh) 1998-06-29 2001-02-28 深圳九先生物工程有限公司 重组人α型复合干扰素及其制备方法和用途
KR100399156B1 (ko) 1999-11-19 2003-09-26 주식회사 엘지생명과학 α-인터페론의 용액제형
CN1175901C (zh) 1999-12-06 2004-11-17 天津华立达生物工程有限公司 一种稳定的干扰素水溶液
US20020043262A1 (en) 2000-08-22 2002-04-18 Alan Langford Spray device
US7544354B2 (en) 2000-10-27 2009-06-09 Novartis Vaccines And Diagnostics Methods of protein purification and recovery
EP1355939A2 (en) 2000-11-03 2003-10-29 Pestka Biomedical Laboratories, Inc. Interferons, uses and compositions related thereto
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US6546074B1 (en) * 2001-03-27 2003-04-08 Astex Technology Limited Protein crystal structure and method for identifying protein modulators
CN1375502A (zh) 2001-10-25 2002-10-23 南京药科大学 聚乙二醇修饰重组人干扰素
US6807478B2 (en) * 2001-12-27 2004-10-19 Koninklijke Philips Electronics N.V. In-building navigation system
CN1176946C (zh) 2002-05-16 2004-11-24 中国人民解放军第二军医大学 一种新型α干扰素
CN1202861C (zh) 2003-07-18 2005-05-25 中国科学院微生物研究所 复合干扰素在治疗sars疾病中的用途
JP2007503812A (ja) 2003-08-28 2007-03-01 ヒュイヤンテック（ユーエスエー），インク． 空間構造によるタンパク質の機能の調節
WO2005067963A1 (en) 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
US20080124302A1 (en) 2005-03-09 2008-05-29 Guangwen Wei Uses of Recombinant Super-Compound Interferons

Also Published As

Publication number Publication date
US7364724B2 (en) 2008-04-29
AU2003248419A1 (en) 2003-11-06
CN1245215C (zh) 2006-03-15
JP4617058B2 (ja) 2011-01-19
CA2439503A1 (en) 2002-10-17
EP1371373B1 (en) 2009-10-21
AU2003248419B2 (en) 2007-01-04
CN1311035A (zh) 2001-09-05
EP1371373A1 (en) 2003-12-17
US8425896B2 (en) 2013-04-23
JP2005508848A (ja) 2005-04-07
EP1371373A4 (en) 2005-05-04
WO2002080958A1 (fr) 2002-10-17
US20110189128A1 (en) 2011-08-04
ATE446104T1 (de) 2009-11-15
DE60234085D1 (de) 2009-12-03
US20080305080A1 (en) 2008-12-11
US20040202641A1 (en) 2004-10-14
US8114395B2 (en) 2012-02-14

Similar Documents

Publication Publication Date Title
HK1061201A1 (en) Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor
CY2019029I1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
AU1593001A (en) Recombinant gelatin in vaccines
CY2014038I1 (el) Αντι-il-6 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
RS100504A (xx) Inhibitori virusa hepatitis c
JP2003522167A5 (xx)
DE60238075D1 (de) Adjuvierte antigene meningokokkenzusammensetzungen
BR0306905A (pt) Vacinas de flavivìrus
GB0114185D0 (en) Compounds
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
DE60139339D1 (de) Stabilisierte interferonzusammensetzungen
AU2002359495A8 (en) Anti-tnf antibodies, compositions, methods and uses
AU2003294757A8 (en) Formulations useful against hepatitis c virus infections
MXPA03007838A (es) Interferon alfa modificado con inmunogenicidad reducida.
ZA200401211B (en) Antigenic compositions
AU2002365269A8 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
IL145279A0 (en) Antibodies against caspase-8, their preparation and use
AU2002235707A1 (en) Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor
AU2002365112A8 (en) Deuterium-based chemiluminescent 1,2-dioxetanes
EP1501870A4 (en) RSV PROTEINS, ANTIBODIES, COMPOSITIONS, PROCESSES AND USES
IT249638Y1 (it) Disposizione di proiettori di luce per l'illuminazione di dipinti.
UA37622A (uk) 1,5-піперидил - 3,7-біс/діетаноламіну/ - піримідил ізовалеріанат, що використовується для діагностики вірусних інфекцій
IL157753A0 (en) Natural antibody active against hiv virus
AU2002350368A1 (en) Method for the hemihydrogenation of dinitriles in order to form aminonitriles
AU2002350370A1 (en) Method for the hemihydrogenation of dinitriles in order to form aminonitriles

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220218